The clinical study titled “A Phase II, Single-arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma” will be conducted at multiple sites within the USA including such prestigious institutions as Vanderbilt University Medical Center. It is anticipated that the first patient will be enrolled this summer.